Biotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease.
Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility in Frankfurt, Germany.
"We are delighted that CHDI has selected PS Biomarker Services to deliver potential proteomic markers that could help elucidate mechanisms of Huntington's disease pathology," said Proteome' Chief Operating Officer Ian Pike.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"The link between the Huntington's disease genotype and disease phenotype remains poorly understood and we will apply our Tandem Mass Tag workflows to provide high density protein expression maps in cell lines carrying different CAG-repeat lengths," he said.
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
